Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Boehringer Innovation Chief Touts R&D Efforts on Undruggable Cancer Targets
December 2, 2019
- Santen Starts Voluntary Recall of Pivalephrine
December 2, 2019
- Takeda Submits Niraparib for Ovarian Cancer in Japan
December 2, 2019
- Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
- 10-Plus Japan Drug Makers Up FY2019 Guidance on Bullish New Drugs, Mainstays: Tally
November 29, 2019
- Rick Kozloski Tapped as President of Alcon Japan
November 29, 2019
- Hisamitsu, Kyowa Kirin Put Off Launch of Haruropi Tape due to Faulty Barcode
November 29, 2019
- Big 4 Drug Wholesalers Raided on Bid-Rigging Charges
November 28, 2019
- Ono Files Tirabrutinib for Add’l Indications in Japan
November 28, 2019
- Ono Seeks to Add 4-Week Dosing to Opdivo Monotherapy
November 28, 2019
- Chugai to End Joint Venture with South Korea's JW Pharma
November 28, 2019
- Chugai Launches Tecentriq 840 mg for Triple-Negative Breast Cancer
November 28, 2019
- ASKA’s Oral Hysteromyoma Drug Shows Non-Inferiority to Leuprorelin in PIII
November 28, 2019
- Sumitomo Dainippon to Launch Global Data Design Office, Leveraging Roivant’s Technology
November 28, 2019
- Otsuka Completes Construction of New Plant in Tokushima
November 28, 2019
- Japan’s First Biosimilars for Nesp, Forteo Hit Shelves
November 27, 2019
- Hisamitsu’s Osteoarthritis Patch Drug Delivers Positive PII Data; PIII Launch Planned in FY2020
November 27, 2019
- Astellas Pharma Grabs China Approval for Xtandi
November 27, 2019
- Kyowa Kirin, Ardelyx Bolster Partnership with Additional Research Deal, US$20 Million Equity Investment
November 27, 2019
- Asahi Kasei to Buy Veloxis for 143.2 Billion Yen, Eyes US Transplant Market
November 26, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…